|Videos|April 19, 2022
Perspectives: FDA Warning Against Renuvion/J-Plasma
Author(s)Linda Stocum, Associate Editor
In this video interview, Darren Smith, MD, comments on the Renuvion/J-Plasma device (Apyx Medical) receiving an FDA warning for dermal resurfacing or skin contraction. He dives into how the device may be causing these issues, how this affects patients, and more.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
2
Targeting MRGPRX2: Early Human Data for a Novel CSU Approach
3
Precision Medicine Arrives in Atopic Dermatitis: Guiding Systemic Treatment Decisions Through Gene Expression Profiling
4
What Counts as “Short-Term” Systemic Corticosteroids in Atopic Dermatitis, and Why It Matters
5